BeStock  
Stocks › Biotechnology › CORT

Corcept Therapeutics CORT

US equityMarket cap rank #1733Biotechnology
$63.62 −$1.36 (-2.09%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $63.62 0.00%
Open$64.07
Prev close$64.98
Day range$62.81 – $65.13
Volume1.09M
Market cap$6.96B
P/E (TTM)47.8
Dividend yield–

Earnings

Average move on report day±7.7%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+27.3%
Worst reaction-10.0%

Stock move on the day after each report

-7.2%2023/Q4+4.9%2024/Q1-1.1%2024/Q2+4.4%2024/Q3-5.6%2024/Q4-4.3%2025/Q1+2.7%2025/Q2+7.8%2025/Q3-0.7%2025/Q4+10.5%2026/Q1+27.3%2026/Q2-3.3%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q33 Nov 2026After Market±12.0%-3.31%Within range
2026/Q229 Jul 2026After Market±12.0%+27.29%Bigger than priced
2026/Q130 Apr 2026After Market±8.0%+10.53%Bigger than priced
2025/Q424 Feb 2026After Market±10.6%-0.71%Within range
2025/Q34 Nov 2025After Market±12.6%+7.81%Within range
2025/Q231 Jul 2025After Market±11.6%+2.72%Within range
2025/Q15 May 2025After Market±12.1%-4.33%Within range
2024/Q426 Feb 2025After Market±23.2%-5.55%Within range
2024/Q330 Oct 2024After Market±18.9%+4.44%Within range
2024/Q229 Jul 2024After Market±15.0%-1.12%Within range
2024/Q11 May 2024After Market±13.1%+4.94%Within range
2023/Q415 Feb 2024After Market±17.8%-7.15%Within range
2023/Q31 Nov 2023After Market±12.3%-9.97%Within range
2023/Q22 Aug 2023After Market±8.9%+24.91%Bigger than priced
2023/Q13 May 2023After Market±10.9%+3.90%Within range
2022/Q428 Feb 2023After Market±11.6%-4.66%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Hypercortisolism Products$208.58M 81.4%
  • Lifyorli$47.56M 18.6%

Latest reported quarter: Q3, ended Sep 2026

Revenue$340.47M+64.0% YoY
Operating profit$114.72M+1,022.7% YoY
Net profit$126.78M+544.6% YoY
Diluted EPS$1.01+531.3% YoY
Free cash flow$142.18M+161.0% YoY
Operating cash flow$142.89M

Revenue, last 8 quarters

$181.9MDec '24$157.2MMar '25$194.4MJun '25$207.6MSep '25$202.1MDec '25$164.9MMar '26$256.1MJun '26$340.5MSep '26

Net profit, last 8 quarters

$30.7MDec '24$20.5MMar '25$35.1MJun '25$19.7MSep '25$24.3MDec '25$-31.8MMar '26$43.0MJun '26$126.8MSep '26

Profitability & balance sheet

Gross margin98.5%
Operating margin11.5%
Net margin16.5%
Return on equity21.7%
Return on assets17.2%
Return on invested capital19.9%
Current ratio3.00
Liabilities / assets19.4%
Cash & investments$370.70M
Total debt$6.97M
Net cash (debt)$363.74M
Free cash flow / sales20.2%

Discussion

No comments yet — be the first to weigh in on CORT.

Sign in to join the discussion.

Scroll to Top